|
|
|
|
| LEADER |
01457nam a2200289 u 4500 |
| 001 |
EB002001757 |
| 003 |
EBX01000000000000001164658 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Clopidogrel and proton pump inhibitor use
|h Elektronische Ressource
|b a review of the evidence on safety
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, 14 March 2017
|
| 300 |
|
|
|a 1 PDF file (49 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Proton Pump Inhibitors / therapeutic use
|
| 653 |
|
|
|a Adult
|
| 653 |
|
|
|a Patient Safety
|
| 653 |
|
|
|a Platelet Aggregation Inhibitors / therapeutic use
|
| 653 |
|
|
|a Percutaneous Coronary Intervention / adverse effects
|
| 653 |
|
|
|a Stents / adverse effects
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK470868
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective of this report is to assess the current evidence on the impact of PPIs on adverse events in adults being treated with clopidogrel dual antiplatelet therapy (DAPT) or monotherapy following percutaneous coronary intervention (PCI) involving stents
|